Skip to content

Clinical efficacy study of pricking and cupping therapy intervention on Stage II breast cancer-related lymphedema after surgery

Clinical efficacy study of pricking and cupping therapy intervention on Stage II breast cancer-related lymphedema after surgery

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000958
Enrollment
Unknown
Registered
2026-04-16
Start date
2026-03-04
Completion date
Unknown
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lymphedema

Interventions

Pressure therapy
Skin care
Control Group:Pressure therapy

Sponsors

Shanghai University of Traditional Chinese Medicine Affiliated Yueyang Integrated Chinese and Western Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 4.1 Women patients who have undergone unilateral breast cancer surgery. 4.2 Those who meet the diagnostic criteria for BCRL. 4.3 BCRL is staged as Grade 2 according to the ISL staging system. 4.4 Age >18 and <80 years old. 4.5 Voluntarily participating in this study, signing the informed consent form, and having the ability to comply with the treatment plan, examinations, and follow-up.

Exclusion criteria

Exclusion criteria: 5.1 Pregnant and/or breastfeeding women; 5.2 Individuals with infection, ulceration, or a tendency to bleed in the skin of the affected upper limb; 5.3 Patients with distant metastasis of breast cancer; 5.4 Patients currently undergoing breast cancer radiotherapy, chemotherapy, or targeted therapy; 5.5 Patients with severe heart, liver, lung, brain, or urinary system diseases, other malignant tumors, or other significant somatic diseases; 5.6 Patients with an expected survival period of less than 3 months; 5.7 Individuals prone to fainting or with allergic constitutions; 5.8 Patients with mental disorders, cognitive impairments, or unwillingness to cooperate; 5.9 Patients who have received other therapies (e.g., medications, CDT treatment, etc.) for upper limb lymphedema within the past month prior to enrollment.

Design outcomes

Primary

MeasureTime frame
Circumference Difference Rate of Affected Side;

Secondary

MeasureTime frame
Skin and subcutaneous tissue thickness;Skin and subcutaneous tissue hardness;Breast Cancer Lymphedema Symptom Index (BCLE-SEI) Scoring System;Upper Limb Function DASH Score Evaluation;Upper Limb Lymphedema Quality of Life (ULLQoL) Scale Scoring;

Countries

China

Contacts

Public ContactSheng Jia Yu

Shanghai University of Traditional Chinese Medicine Affiliated Yueyang Integrated Chinese and Western Medicine Hospital

sjy1983sh@126.com13361990930

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026